Our top pick for
Chembio Diagnostics, Inc is a diagnostics & research business based in the US. Chembio Diagnostics shares (CEMI) are listed on the NASDAQ and all prices are listed in US Dollars. Chembio Diagnostics employs 324 staff and has a trailing 12-month revenue of around USD$29.1 million.
|Latest market close||USD$5.5|
|52-week range||USD$2.25 - USD$15.89|
|50-day moving average||USD$5.4368|
|200-day moving average||USD$5.0352|
|Wall St. target price||USD$9|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-0.73|
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-01-11)||3.38%|
|1 month (2020-12-18)||5.5|
|3 months (2020-10-16)||13.40%|
|6 months (2020-07-17)||10.00%|
|1 year (2020-01-17)||41.03%|
|2 years (2019-01-18)||-21.99%|
|3 years (2018-01-18)||8.75|
|5 years (2016-01-15)||27.91%|
|Revenue TTM||USD$29.1 million|
|Gross profit TTM||USD$3.5 million|
|Return on assets TTM||-18.13%|
|Return on equity TTM||-74.57%|
|Market capitalisation||USD$104.5 million|
TTM: trailing 12 months
There are currently 3.9 million Chembio Diagnostics shares held short by investors – that's known as Chembio Diagnostics's "short interest". This figure is 7.3% up from 3.6 million last month.
There are a few different ways that this level of interest in shorting Chembio Diagnostics shares can be evaluated.
Chembio Diagnostics's "short interest ratio" (SIR) is the quantity of Chembio Diagnostics shares currently shorted divided by the average quantity of Chembio Diagnostics shares traded daily (recently around 2.4 million). Chembio Diagnostics's SIR currently stands at 1.6. In other words for every 100,000 Chembio Diagnostics shares traded daily on the market, roughly 1600 shares are currently held short.
However Chembio Diagnostics's short interest can also be evaluated against the total number of Chembio Diagnostics shares, or, against the total number of tradable Chembio Diagnostics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Chembio Diagnostics's short interest could be expressed as 0.19% of the outstanding shares (for every 100,000 Chembio Diagnostics shares in existence, roughly 190 shares are currently held short) or 0.1953% of the tradable shares (for every 100,000 tradable Chembio Diagnostics shares, roughly 195 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Chembio Diagnostics.
Find out more about how you can short Chembio Diagnostics stock.
We're not expecting Chembio Diagnostics to pay a dividend over the next 12 months.
Chembio Diagnostics's shares were split on a 1:8 basis on 30 May 2012. So if you had owned 8 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Chembio Diagnostics shares – just the quantity. However, indirectly, the new 700% higher share price could have impacted the market appetite for Chembio Diagnostics shares which in turn could have impacted Chembio Diagnostics's share price.
Over the last 12 months, Chembio Diagnostics's shares have ranged in value from as little as $2.25 up to $15.89. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Chembio Diagnostics's is 2.1024. This would suggest that Chembio Diagnostics's shares are significantly more volatile than the average for this exchange and represent a higher risk.
Chembio Diagnostics, Inc., together with its subsidiaries, develops, manufactures, and commercializes point-of-care (POC) diagnostic tests that are used to detect or diagnose diseases. The company offers tests for HIV and Syphilis, and Zika virus. It also develops tests for malaria, Dengue virus, chikungunya virus, ebola, lassa, marburg, leptospirosis, Rickettsia typhi, Burkholderia pseudomallei, and Orientia tsutsugamushi. In addition, the company develops tests for a specific form of cancer, concussion, and bovine tuberculosis; and handheld optical analyzers for rapid diagnostic tests. It sells its products under the STAT-PAK, SURE CHECK, STAT VIEW, or DPP trademarks, as well as under the private labels of its marketing partners to medical laboratories and hospitals, governmental and public health entities, non-governmental organizations, medical professionals, and retail establishments in the United States and internationally. The company has collaboration agreements with Concussion Science Group Division of Perseus Science Group LLC to develop a POC diagnostic test for traumatic brain injury; Foundation for Innovative New Diagnostics to develop a POC fever panel assay for life-threatening acute febrile illnesses; AstraZeneca to develop a POC test for eosinophilic respiratory disease; and Shire Human Genetic Therapies, Inc. to develop a novel POC diagnostic test. It also has a strategic partnership with LumiraDx Limited to develop point-of-care diagnostic tests for the detection of the COVID-19 virus, and IgM and IgG antibodies on the LumiraDx and Chembio DPP platforms. Chembio Diagnostics, Inc. was founded in 1985 and is headquartered in Hauppauge, New York.
Everything we know about the CDT Environmental Technology Investment Holdings Limited IPO, plus information on how to buy in.
Everything we know about the Viant Technology Inc IPO, plus information on how to buy in.
Steps to owning and managing EVGN, with 24-hour and historical pricing before you buy.
Steps to owning and managing ETL, with 24-hour and historical pricing before you buy.
Steps to owning and managing EQBK, with 24-hour and historical pricing before you buy.
Steps to owning and managing EIGI, with 24-hour and historical pricing before you buy.
Steps to owning and managing ELTK, with 24-hour and historical pricing before you buy.
Steps to owning and managing DNKN, with 24-hour and historical pricing before you buy.
Steps to owning and managing DKL, with 24-hour and historical pricing before you buy.
Steps to owning and managing DMAC, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.